Breaking News

Samsung Bioepis, Epis NexLab Partner with G2GBIO to Develop Novel Semaglutide Assets

Will advance novel assets based on G2GBIO’s proprietary microsphere technology.

Author Image

By: Charlie Sternberg

Associate Editor

Samsung Bioepis Co. Ltd. and Epis NexLab Co. Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings, have entered a research collaboration and license agreement with G2GBIO, a company specializing in the development of sustained-release formulations, to develop novel assets based on G2GBIO’s proprietary microsphere technology. Under the agreement, Samsung Bioepis will be given a full license right for the novel long-acting semaglutide asset, and an option to license another ass...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters